Sign in
4

Changes in Ownership

Maze Therapeutics, Inc. Filed Acc 0001415889-25-002956

Director acquired 36,946 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
HOMCY CHARLES J Director 2025-02-03 Conversion +8,807 37,330 D: show line 1 in the form
HOMCY CHARLES J Director 2025-02-03 Conversion +20,717 58,047 D: show line 2 in the form
HOMCY CHARLES J Director 2025-02-03 Conversion +7,422 7,422 I: show line 3 in the form

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
HOMCY CHARLES J Director 2025-02-03 Conversion · Series B Preferred Stock −72,727 0 D: show line 4 in the form
HOMCY CHARLES J Director 2025-02-03 Conversion · Series C Preferred Stock −169,405 0 D: show line 5 in the form
HOMCY CHARLES J Director 2025-02-03 Conversion · Series D-1 Preferred Stock −71,564 0 I: show line 6 in the form
HOMCY CHARLES J Director 2024-11-26 Conversion · Series D-1 Preferred Stock +71,564 7,422 I: show line 7 in the form
HOMCY CHARLES J Director 2024-11-26 Conversion · 8% Convertible Note due 2026 −0 $78,961.64 $0 I: show line 8 in the form
HOMCY CHARLES J Director 2024-12-09 Grant or award · Stock Option (Right to Buy) +80,385 80,385 D: show line 9 in the form
HOMCY CHARLES J Director 2024-12-09 Returned to the company · Stock Option (Right to Buy) −80,385 0 D: show line 10 in the form
HOMCY CHARLES J Director 2024-12-09 Grant or award · Stock Option (Right to Buy) +5,704 5,704 D: show line 11 in the form
Loading xslF345X05/form4-02042025_090216.xml…